Azacitidine in high-risk MDS patients. A "real life" experience from a single center

被引：1
|
作者：
Greco, R. [1 ]
Riva, M. [1 ]
Ravano, E. [1 ]
Molteni, A. [1 ]
Morra, E. [1 ]
机构：
[1] Osped Niguarda Ca Granda, Ematol, Milan, Italy
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70346-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-299
引用
收藏
页码：S157 / S157
页数：1
相关论文
共 50 条
  • [21] Prognostic impact of elevated pretreatment serum ferritin in patients with high-risk MDS treated with azacitidine
    Laribi, Kamel
    Bolle, Delphine
    Alani, Mustapha
    Ghnaya, Habib
    Le Bourdelles, Saga
    Besancon, Anne
    Farhi, Jonathan
    Denizon, Nathalie
    de Materre, Alix Baugier
    EXPERIMENTAL HEMATOLOGY, 2018, 65 : 34 - 37
  • [22] Percutaneous revascularization for left main disease in real-life high-risk patients: A single center study
    Hernandez, Felipe
    Rodriguez, Sergio
    Mora, Laura
    Martin, Roberto
    Andreu, Javier
    Albarran, Agustin
    Garcia-Tejada, Julio
    Velazquez, Maite
    Tascon, Juan
    AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (8A): : 161M - 161M
  • [23] EXPERIENCE OF A CENTER WITH THE USE OF AZACITIDINE IN PATIENTS WITH MDS. ANALYSIS WITH LARGE MONITORING
    Antonieta, Molero
    Bryan, Merchan
    Julia, Montoro
    Margarita, Ortega
    Laura, Gallur
    David, Valcarcel
    HAEMATOLOGICA, 2016, 101 : 151 - 151
  • [24] Oral Azacitidine Maintenance after Front-Line Treatment with Azacitidine and Venetoclax in Elderly AML Patients. Single Center Experience
    Gardeney, Helene
    Torregrosa, Jose
    Brechet, Maud
    Moya, Niels
    Dindinaud, Elodie
    Basle, Caroline
    Raimbault, Anna
    Hernanz, Maria Pilar Gallego
    BLOOD, 2024, 144 : 5947 - 5948
  • [25] The outcome of allogeneic stem cell transplantation in patients with high risk MDS and AML: single center experience
    Halahleh, Khalid
    Odaily, Sarah
    Al Tell, Abdallah
    Al-Awabdeh, Tala
    Ma'kosa, Mohammad
    Najjar, Rula
    Rihani, Rawad
    Abu Shanab, Mayada
    Hussein, Nilly
    Khattab, Eman
    Sharma, Shanta
    Abu Khader, Ahmad
    Yousef, Dana
    Abu-Jazar, Husam
    Tbakhi, Abdelghani
    Sarhan, Mahmoud
    BONE MARROW TRANSPLANTATION, 2018, 53 : 189 - 190
  • [26] Clonal evolution in high-risk MDS and secondary AML treated with venetoclax and azacitidine
    Koch, R.
    Ganster, C.
    Dierks, S.
    Shirneshan, K.
    Rittscher, K.
    Nothnick, G.
    Becker, S.
    Shumilov, E.
    Haase, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 199 - 199
  • [27] AZACITIDINE IN 'REAL LIFE' PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A SINGLE CENTRE EXPERIENCE
    Tendas, A.
    Cupelli, L.
    Piccioni, D.
    Caravita, T.
    Siniscalchi, A.
    Del Poeta, G.
    Scaramucci, L.
    Giovannini, M.
    Dentamaro, T.
    Perrotti, A.
    Fratoni, S.
    de Fabritiis, P.
    Niscola, P.
    HAEMATOLOGICA, 2014, 99 : 621 - 622
  • [28] A Single-Center Experience of Overseas Kidney Transplant for Immunologically High-Risk Patients
    Jung, Cheol Woong
    Park, Kwan Tae
    Jun, Heungman
    Kim, Su Yeon
    Kim, Su Jin
    Kim, Myung-Gyu
    Jo, Sang-kyung
    Cho, Wonyong
    Kim, Hyoung Kyu
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2015, 13 : 251 - 255
  • [29] Feasibility and Safety of Bariatric Surgery in High-Risk Patients: A Single-Center Experience
    Moulla, Yusef
    Lyros, Orestis
    Blueher, Matthias
    Simon, Philipp
    Dietrich, Arne
    JOURNAL OF OBESITY, 2018, 2018
  • [30] SOMATIC MUTATION DYNAMICS IN HIGH-RISK MDS PATIENTS TREATED WITH AZACITIDINE IDENTIFIED VIA SERIAL SAMPLING
    Polgarova, K.
    Vargova, K.
    Kulvait, V.
    Dusilkova, N.
    Minarik, L.
    Zemanova, Z.
    Jonasova, A.
    Stopka, T.
    HAEMATOLOGICA, 2017, 102 : 478 - 478
12345